"Antineoplastic Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Substances that inhibit or prevent the proliferation of NEOPLASMS.
| Descriptor ID |
D000970
|
| MeSH Number(s) |
D27.505.954.248
|
| Concept/Terms |
Antineoplastic Agents- Antineoplastic Agents
- Agents, Antineoplastic
- Antineoplastic Drugs
- Drugs, Antineoplastic
- Antineoplastics
- Chemotherapeutic Anticancer Drug
- Drug, Chemotherapeutic Anticancer
- Antitumor Drugs
- Drugs, Antitumor
- Cancer Chemotherapy Agents
- Agents, Cancer Chemotherapy
- Chemotherapy Agents, Cancer
- Cancer Chemotherapy Drugs
- Chemotherapy Drugs, Cancer
- Drugs, Cancer Chemotherapy
- Chemotherapeutic Anticancer Agents
- Agents, Chemotherapeutic Anticancer
- Anticancer Agents
- Agents, Anticancer
- Antitumor Agents
- Agents, Antitumor
|
Below are MeSH descriptors whose meaning is more general than "Antineoplastic Agents".
Below are MeSH descriptors whose meaning is more specific than "Antineoplastic Agents".
This graph shows the total number of publications written about "Antineoplastic Agents" by people in this website by year, and whether "Antineoplastic Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 1 | 1 | 2 |
| 1995 | 11 | 3 | 14 |
| 1996 | 14 | 2 | 16 |
| 1997 | 4 | 2 | 6 |
| 1998 | 7 | 3 | 10 |
| 1999 | 12 | 3 | 15 |
| 2000 | 11 | 5 | 16 |
| 2001 | 7 | 4 | 11 |
| 2002 | 10 | 8 | 18 |
| 2003 | 16 | 8 | 24 |
| 2004 | 16 | 7 | 23 |
| 2005 | 31 | 10 | 41 |
| 2006 | 19 | 13 | 32 |
| 2007 | 30 | 11 | 41 |
| 2008 | 28 | 8 | 36 |
| 2009 | 24 | 15 | 39 |
| 2010 | 24 | 9 | 33 |
| 2011 | 27 | 12 | 39 |
| 2012 | 24 | 6 | 30 |
| 2013 | 29 | 11 | 40 |
| 2014 | 25 | 11 | 36 |
| 2015 | 24 | 11 | 35 |
| 2016 | 20 | 12 | 32 |
| 2017 | 38 | 9 | 47 |
| 2018 | 28 | 9 | 37 |
| 2019 | 19 | 12 | 31 |
| 2020 | 26 | 3 | 29 |
| 2021 | 16 | 7 | 23 |
| 2022 | 10 | 1 | 11 |
| 2023 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antineoplastic Agents" by people in Profiles.
-
An anti-HER2 biparatopic antibody that induces unique HER2 clustering and complement-dependent cytotoxicity. Nat Commun. 2023 Mar 13; 14(1):1394.
-
Inhibition of the MNK1/2-eIF4E Axis Augments Palbociclib-Mediated Antitumor Activity in Melanoma and Breast Cancer. Mol Cancer Ther. 2023 02 01; 22(2):192-204.
-
Obesity reduced survival with 5-fluorouracil and did not protect against chemotherapy-induced cachexia or immune cell cytotoxicity in mice. Cancer Biol Ther. 2022 12 31; 23(1):1-15.
-
ONC201-Induced Mitochondrial Dysfunction, Senescence-like Phenotype, and Sensitization of Cultured BT474 Human Breast Cancer Cells to TRAIL. Int J Mol Sci. 2022 Dec 08; 23(24).
-
Inhibition of CDK8/19 Mediator kinase potentiates HER2-targeting drugs and bypasses resistance to these agents in?vitro and in?vivo. Proc Natl Acad Sci U S A. 2022 08 09; 119(32):e2201073119.
-
Application of Pharmacokinetic Prediction Platforms in the Design of Optimized Anti-Cancer Drugs. Molecules. 2022 Jun 08; 27(12).
-
Disulfiram oxy-derivatives induce entosis or paraptosis-like death in breast cancer MCF-7 cells depending on the duration of treatment. Biochim Biophys Acta Gen Subj. 2022 09; 1866(9):130184.
-
A pilot study of genomic-guided induction therapy followed by immunotherapy with difluoromethylornithine maintenance for high-risk neuroblastoma. Cancer Rep (Hoboken). 2022 Nov; 5(11):e1616.
-
Recent advances and limitations in the application of kahalalides for the control of cancer. Biomed Pharmacother. 2022 Apr; 148:112676.
-
A Selective and Orally Bioavailable Quinoline-6-Carbonitrile-Based Inhibitor of CDK8/19 Mediator Kinase with Tumor-Enriched Pharmacokinetics. J Med Chem. 2022 02 24; 65(4):3420-3433.